Halozyme Therapeutics, Inc. (HALO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 268 | 443 | 660 | 829 | 1,015 | 1,397 | 1,664 | 1,839 |
| Operating profit | $m | 816 | 944 | ||||||
| Net profit | $m | 129 | 403 | 202 | 282 | 444 | 317 | 414 | 1,043 |
| EPS reported | $ | 2.56 | 3.35 | ||||||
| Operating cashflow per share | $ | 5.44 | 6.98 | ||||||
| Capex per share | $ | 0.06 | 0.11 | ||||||
| FCF per share | $ | 5.38 | 6.87 | ||||||
| Free cash flow | $m | 645 | 806 | ||||||
| Net debt | $m | 2,000 | 1,916 | ||||||
| Book value equity | $m | 49 | 144 | ||||||
| Book value per share | $ | 0.39 | 1.18 | ||||||
| Number of shares | m | 123.9 | 121.22 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 26.29 | 34.00 | ||||||
| P/B LTM | x | 165.22 | 56.19 | ||||||
| P/S LTM | x | 5.77 | 4.85 | ||||||
| P/FCF LTM | x | 12.51 | 10.00 | ||||||
| EV/EBITDA LTM | x | 17.58 | 14.11 | ||||||
| EV/Sales LTM | x | 7.21 | 8.23 | ||||||
| Earnings Yield LTM | % | +3.80% | +2.94% | ||||||
| FCF Yield | % | +7.99% | +10.00% | ||||||
| Quality | |||||||||
| ROE | % | +649.18% | +180.63% | ||||||
| ROIC | % | +23.59% | +27.42% | ||||||
| Operating margin | % | +58.45% | +56.77% | ||||||
| Gross margin | % | +78.13% | +78.18% | ||||||
| FCF/Sales | % | +46.15% | +48.46% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -25.36% | -2.33% | ||||||
| Sales Growth YoY | % | +37.55% | +63.86% | ||||||
| Net Income Growth YoY | % | -28.64% | -6.87% | ||||||
| FCF Growth | % | +37.62% | +72.13% | ||||||
| Operating Profit Growth | % | +48.02% | +71.27% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.30 | 0.38 | ||||||
| Net Debt/EBITDA | x | 3.51 | 2.78 | ||||||
| EBIT/Net interest | x | 45.03 | 46.52 | ||||||
| Net debt/market cap | % | +26.57% | +18.34% | ||||||
| Net debt/Equity | x | 40.97 | 13.35 | ||||||
| Gross debt/equity | x | 43.89 | 14.95 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Halozyme Therapeutics, Inc. (HALO)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free